Evaluating the timing of cancer treatment after COVID-19 infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety of starting antitumor therapy in patients who have recently recovered from COVID-19, as indicated by a negative nucleic acid test. It will investigate whether early initiation of treatment increases adverse events or the risk of COVID-19 re-infection, as well as its impact on the quality of life of these patients. Participants will provide information on their COVID-19 symptoms, diagnosis dates, and quality of life before and during their infection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31.
* COVID-19 was confirmed by antigen testing or nucleic acid testing.
* Tumor was confirmed by pathology.
* Patients received systemic antitumor therapy after infected with COVID-19.

Exclusion Criteria:

* COVID-19 was not confirmed by antigen testing or nucleic acid testing
* Tumor was not confirmed by pathology
* Patients did not receive systemic antitumor therapy
* Patients died before receiving systemic antitumor therapy

Where it's running

• Seventh Affiliated Hospital, Sun Yat-sen University
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Principal investigator: Bo Wang — The Seventh Affiliated Hospital of Sun Yat-sen University
• Study coordinator: Xiaofen Pan, MD
• Email: panxf8@mail.sysu.edu.cn
• Phone: +8618124671750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.